JP2008502633A - Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン - Google Patents
Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン Download PDFInfo
- Publication number
- JP2008502633A JP2008502633A JP2007515878A JP2007515878A JP2008502633A JP 2008502633 A JP2008502633 A JP 2008502633A JP 2007515878 A JP2007515878 A JP 2007515878A JP 2007515878 A JP2007515878 A JP 2007515878A JP 2008502633 A JP2008502633 A JP 2008502633A
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- vlp
- composition
- vaccine
- cancer type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims description 76
- 239000000203 mixture Substances 0.000 claims abstract description 110
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 76
- 201000011510 cancer Diseases 0.000 claims abstract description 73
- 230000002163 immunogen Effects 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 12
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 10
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 8
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 description 248
- 241000341655 Human papillomavirus type 16 Species 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 208000015181 infectious disease Diseases 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 150000007949 saponins Chemical class 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- 229930182490 saponin Natural products 0.000 description 16
- 235000017709 saponins Nutrition 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 15
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 238000001514 detection method Methods 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000002380 cytological effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000005571 anion exchange chromatography Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 206010008263 Cervical dysplasia Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 208000037581 Persistent Infection Diseases 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101150075239 L1 gene Proteins 0.000 description 3
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 229940033278 HPV-16/18 vaccine Drugs 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000255985 Trichoplusia Species 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013264 cohort analysis Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 102220047090 rs6152 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 208000020077 squamous cell intraepithelial neoplasia Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413510.9A GB0413510D0 (en) | 2004-06-16 | 2004-06-16 | Vaccine |
| US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
| PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012001102A Division JP2012102132A (ja) | 2004-06-16 | 2012-01-06 | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008502633A true JP2008502633A (ja) | 2008-01-31 |
Family
ID=35160037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515878A Pending JP2008502633A (ja) | 2004-06-16 | 2005-06-14 | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1758609B1 (enExample) |
| JP (1) | JP2008502633A (enExample) |
| KR (1) | KR20070029254A (enExample) |
| AR (1) | AR049354A1 (enExample) |
| AU (1) | AU2005253723B2 (enExample) |
| BR (1) | BRPI0512042B8 (enExample) |
| CA (1) | CA2566620C (enExample) |
| FR (2) | FR15C0082I2 (enExample) |
| IL (1) | IL179138A0 (enExample) |
| LU (3) | LU92899I2 (enExample) |
| MA (1) | MA28692B1 (enExample) |
| MX (1) | MXPA06014515A (enExample) |
| NO (1) | NO20070195L (enExample) |
| PE (1) | PE20060434A1 (enExample) |
| PL (1) | PL1758609T3 (enExample) |
| RU (1) | RU2420313C2 (enExample) |
| SG (1) | SG153837A1 (enExample) |
| WO (1) | WO2005123125A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529475A (ja) * | 2008-07-31 | 2011-12-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 抗ｈｐｖワクチン |
| JP2013540421A (ja) * | 2010-07-15 | 2013-11-07 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | ヒトパピローマウイルスｅ７抗原組成物およびその使用 |
| JP2017531699A (ja) * | 2014-10-24 | 2017-10-26 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | 癌および皮膚病変の治療 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013475A (es) * | 2005-04-26 | 2008-04-02 | Glaxosmithkline Biolog Sa | Vacuna. |
| US9566323B2 (en) * | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| EP3269388A1 (en) | 2012-10-30 | 2018-01-17 | Pfizer Inc. | Recombinant particle based vaccines against human cytomegalovirus infection |
| CN107188966B (zh) | 2016-03-15 | 2020-03-31 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087614A2 (en) * | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| JP2003508495A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
| JP2003508494A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
| WO2003078455A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus like particle from papillomavirus and their use in vaccine |
| WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| PT1572233E (pt) * | 2002-12-20 | 2011-06-07 | Glaxosmithkline Biolog Sa | Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
-
2005
- 2005-06-14 KR KR1020077001065A patent/KR20070029254A/ko not_active Ceased
- 2005-06-14 EP EP05757953A patent/EP1758609B1/en not_active Expired - Lifetime
- 2005-06-14 RU RU2006143804/10A patent/RU2420313C2/ru active
- 2005-06-14 BR BRPI0512042A patent/BRPI0512042B8/pt not_active IP Right Cessation
- 2005-06-14 AR ARP050102434A patent/AR049354A1/es not_active Application Discontinuation
- 2005-06-14 AU AU2005253723A patent/AU2005253723B2/en active Active
- 2005-06-14 PE PE2005000677A patent/PE20060434A1/es not_active Application Discontinuation
- 2005-06-14 WO PCT/EP2005/006461 patent/WO2005123125A1/en not_active Ceased
- 2005-06-14 PL PL05757953T patent/PL1758609T3/pl unknown
- 2005-06-14 SG SG200904200-3A patent/SG153837A1/en unknown
- 2005-06-14 MX MXPA06014515A patent/MXPA06014515A/es active IP Right Grant
- 2005-06-14 JP JP2007515878A patent/JP2008502633A/ja active Pending
- 2005-06-14 CA CA2566620A patent/CA2566620C/en not_active Expired - Lifetime
-
2006
- 2006-11-09 IL IL179138A patent/IL179138A0/en unknown
- 2006-12-28 MA MA29576A patent/MA28692B1/fr unknown
-
2007
- 2007-01-11 NO NO20070195A patent/NO20070195L/no not_active Application Discontinuation
-
2015
- 2015-12-04 FR FR15C0082C patent/FR15C0082I2/fr active Active
- 2015-12-04 FR FR15C0084C patent/FR15C0084I2/fr active Active
- 2015-12-08 LU LU92899C patent/LU92899I2/xx unknown
- 2015-12-08 LU LU92900C patent/LU92900I2/xx unknown
- 2015-12-08 LU LU92898C patent/LU92898I2/xx unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508495A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
| JP2003508494A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
| WO2002087614A2 (en) * | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| WO2003078455A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus like particle from papillomavirus and their use in vaccine |
| WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
Non-Patent Citations (4)
| Title |
|---|
| JPN6012013397; 臨床とウイルス Ｖｏｌ．１０，Ｎｏ．１, 1982, ｐ４５-４９ |
| JPN6012013400; Ｂｉｋｅｎ Ｊｏｕｒｎａｌ Ｖｏｌ．１７，Ｎｏ．４, 1974, ｐ１６１-１６７ |
| JPN6012013403; Ｊｏｕｒｎａｌ ｏｆ Ｉｎｆｅｃｔｉｏｕｓ Ｄｉｓｅａｓｅｓ Ｖｏｌ．１８０，Ｎｏ．６, 1999, ｐ２０１８-２０２２ |
| JPN6012013406; Ｖａｃｃｉｎｅ Ｖｏｌ．４，Ｎｏ．４, 1986, ｐ２３３-２３６ |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529475A (ja) * | 2008-07-31 | 2011-12-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 抗ｈｐｖワクチン |
| JP2013540421A (ja) * | 2010-07-15 | 2013-11-07 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | ヒトパピローマウイルスｅ７抗原組成物およびその使用 |
| JP2017531699A (ja) * | 2014-10-24 | 2017-10-26 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | 癌および皮膚病変の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006143804A (ru) | 2008-08-20 |
| LU92899I2 (fr) | 2016-03-08 |
| AR049354A1 (es) | 2006-07-19 |
| CA2566620A1 (en) | 2005-12-29 |
| WO2005123125A1 (en) | 2005-12-29 |
| CA2566620C (en) | 2014-03-11 |
| MXPA06014515A (es) | 2007-03-23 |
| FR15C0082I2 (fr) | 2016-10-28 |
| EP1758609A1 (en) | 2007-03-07 |
| AU2005253723B2 (en) | 2011-01-20 |
| LU92900I2 (fr) | 2016-03-08 |
| BRPI0512042A (pt) | 2008-02-06 |
| PE20060434A1 (es) | 2006-06-08 |
| AU2005253723A1 (en) | 2005-12-29 |
| KR20070029254A (ko) | 2007-03-13 |
| BRPI0512042B1 (pt) | 2019-01-22 |
| LU92898I2 (fr) | 2016-03-08 |
| RU2420313C2 (ru) | 2011-06-10 |
| IL179138A0 (en) | 2007-03-08 |
| FR15C0082I1 (fr) | 2016-01-08 |
| EP1758609B1 (en) | 2012-10-03 |
| PL1758609T3 (pl) | 2013-02-28 |
| FR15C0084I1 (enExample) | 2016-01-08 |
| SG153837A1 (en) | 2009-07-29 |
| FR15C0084I2 (fr) | 2016-10-28 |
| NO20070195L (no) | 2007-01-15 |
| MA28692B1 (fr) | 2007-06-01 |
| BRPI0512042B8 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050287161A1 (en) | Vaccine | |
| JP2012102132A (ja) | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン | |
| EP1758609B1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
| US20090181052A1 (en) | Vaccine | |
| US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
| CN100418577C (zh) | Hpv-16和hpv-18l1vlp疫苗 | |
| US7858098B2 (en) | Vaccine | |
| CN101217976A (zh) | 疫苗 | |
| CN101217975A (zh) | 疫苗 | |
| WO2006114273A2 (en) | Vaccine | |
| BRPI0610032A2 (pt) | uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit | |
| BRPI0610396A2 (pt) | vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110426 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120106 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120123 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120316 |